Improving CAR T cell therapy for better tracking and effectiveness
Interrogating the in vivo pharmacokinetics of armored CARs with radiohapten capture
This study is looking at ways to make CAR T cell therapy better for patients with tough-to-treat B-cell cancers by using special imaging techniques to see how well the treatment is working and to help the engineered T cells find and attack the cancer cells more effectively.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11275273 on NIH RePORTER |
What this research studies
This research focuses on enhancing CAR T cell therapy, particularly for patients with B-cell malignancies who may not respond well to current treatments. The team is developing a method to track these engineered T cells in the body using advanced imaging techniques, which will help determine how well the therapy is working and if adjustments are needed. By using a special reporter system, they aim to improve the ability of CAR T cells to target and kill cancer cells, especially in cases where tumors may not express the targeted antigen. This approach could lead to more effective treatments and better outcomes for patients facing treatment-resistant cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with B-cell malignancies who have limited responses to current CAR T cell therapies or are at risk of tumor relapse.
Not a fit: Patients with non-B-cell malignancies or those who are not eligible for CAR T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective CAR T cell therapies that improve patient outcomes in treating B-cell malignancies.
How similar studies have performed: Previous research has shown promising results with CAR T cell therapies, but this specific approach using radiohapten capture is novel and has not been extensively tested in patients.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Krebs, Simone — University of Tx Md Anderson Can Ctr
- Study coordinator: Krebs, Simone
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.